IBEX 35
11.102,80 +70,50 (+0,64%) Euro Stoxx 50
4.942,94 +35,64 (+0,73%) Dólar/Euro
1,0742 +0,0045 (+0,42%) Petróleo Brent
85,12 -0,12 (-0,14%) Oro
2.339,80 +8,60 (+0,37%) Bitcoin EUR
56.801,68 -3.075,20 (-5,14%)
Cotinga Pharmaceuticals Inc. (COTQF)
Cotinga Pharmaceuticals Inc.
The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
https://www.cotingapharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Descripción
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Gobierno corporativo
El ISS Governance QualityScore de Cotinga Pharmaceuticals Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
